Displaying 13 - 24 of 76
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
1

Novo Nordisk: "Walking the clinical care pathway for NASH: learnings from implementation" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
1

Novo Nordisk and Echosens: "Clinical challenge: Updates on the non-invasive toolbox for NASH and Fibrosis" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023

View
Displaying 13 - 24 of 76